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Erythropoietin (Epo) and vascular growth factor (VEGF) are known to be involved in the regulation of cellular activity when
oxygen transport is reduced as in anaemia or hypoxic conditions. Because it has been suggested that Epo could play a role in
skeletal muscle development, regeneration, and angiogenesis, we aimed to assess Epo deﬁciency in both normoxia and hypoxia
by using an Epo-deﬁcient transgenic mouse model (Epo-TAg
h). Histoimmunology, ELISA and real time RT-PCR did not show
any muscle ﬁber atrophy or accumulation of active HIF-1α but an improvement of microvessel network and an upregulation of
VEGFR2 mRNA in Epo-deﬁcient gastrocnemius compared with Wild-Type one. In hypoxia, both models exhibit an upregulation
of VEGF120 and VEGFR2 mRNA but no accumulation of Epo protein. EpoR mRNA is not up-regulated in both Epo-deﬁcient
and hypoxic gastrocnemius. These results suggest that muscle deconditioning observed in patients suﬀering from renal failure is
not due to Epo deﬁciency.
1.Introduction
Erythropoietin (Epo) is know as a key-regulator of erythro-
poiesisstimulatingproliferation,diﬀerentiation,andsurvival
growth of erythroid precursor resulting in the increased
production of red blood cells [1]. In both men and mice
exposed to altitude, plasma Epo concentration reached a
peakaftera24-hourperiodofexposure[2]andsubsequently
declininginaprogressivemannerwithindaysorweeks[3,4].
It has been demonstrated the relative importance of altitude
Epo-induced polycythemia in the process of acclimatisation
to altitude hypoxia performed between days 4 and 9 of
exposure [2].
Through speciﬁc binding to its receptor (EpoR), Epo
triggers a chain of intracellular signaling events that depends
on activation of Jak2 tyrosine kinase [5]. Studies dealing
with the expression of EpoR revealed a role for Epo, in
addition to erythropoiesis, on various tissues such as those
of the central nervous system, pancreas, liver, lung, smooth,
cardiac and skeletal muscles (for review see [6]). As a result,
the eﬀects of Epo as growth factor, antiapoptotic factor or
angiogenic factor on these tissues are considered of a great
interest.
Indeed, the EpoR has been identiﬁed in mouse C2C12
primary myoblast cultures [7]a sw e l la si nh u m a ns k e l e t a l
muscle [8]. On both C2C12 cells and primary cultures
of mouse myoblasts, Epo activates the proliferation of
myogenic precursor cells [7]. More recently, the injection
of recombinant human Epo (rHuEpo) has been shown to
improve the regeneration process of rat soleus muscle [9].
Taken together, these results suggest a role for Epo on the
development and regeneration of skeletal muscle.2 Journal of Biomedicine and Biotechnology
Epo was shown to have the same angiogenic power
as vascular endothelial growth factor (VEGF) [10]. Kertesz
et al. [11] demonstrated the role of Epo and VEGF
in the formation of new blood vessels during the early
development of tissues. Using Epo knock-out mutant, these
authors showed that angiogenesis was defective while the
vasculogenesis was relatively normal. On the other hand,
Suzuki et al. [12] observed that the nonhematopoietic
role of Epo is dispensable to organism development and
angiogenesis under normal conditions. From those data, we
suggest a compensatory mechanism to Epo deﬁciency in
tissues. Then we may hypothesise that the default of oxygen
transport to tissues leads to local hypoxia which induces the
accumulation of Hypoxia-Inducible Factor-1α (HIF-1α)a n d
then the expression of the angiogenic factor VEGF as shown
in anemic brain [13].
The VEGF-A (also referred as VEGF) protein comprises
various isoforms of 121 to 206 amino acids in humans (120
to 205 in rodents), produced by alternative splicing during
transcription [14, 15]. The 120, 164 and 188 isoforms are
the most frequently expressed ones although each one has
speciﬁc biological activities [16, 17]. VEGF121 is a freely
diﬀusible protein whereas VEGF189 is almost completely
sequestered in the extracellular matrix (ECM). VEGF165
has intermediate properties, as it is moderately diﬀusible
but a signiﬁcant fraction remains bound to the cell surface
and ECM. Actually, the longer forms of VEGF are stably
incorporated to the ECM but can be released in a diﬀusible
form by several agents [18].
Epo deﬁciency is observed in patients suﬀering from
severe renal failure inducing intense anaemia. Skeletal
muscles of these patients present structural and functional
abnormalities that contribute to explain, at least partly,
their impaired exercise capacity, muscle deconditioning and
decreasedresistancetofatigue.Thereisareductioninmuscle
mass associated with myoﬁber atrophy, mainly in type II
ﬁbers [19, 20]. Moreover, reductions in muscle capillarity,
as well as abnormalities of mitochondria are contributing
factors for muscle fatigability [19–21]. Although muscle
deconditioninginthosepatientscouldalsobeduetophysical
inactivity [20], those results suggest that Epo deﬁciency
could have consequences on muscle structure and capillar-
isation.
In order to understand whether Epo is an important fac-
tor for muscle and capillary development and maintenance
in hypoxia, we propose to use a model of erythropoietin-
SV40 T antigen (Epo-TAgh) transgenic mice with a targeted
disruption in the 5  untranslated region of the Epo gene
that dramatically reduces its expression [22, 23] and then
induces severe anaemia. We aim to assess whether Epo
deﬁciency alters skeletal muscle structure in either normoxia
or hypoxia.
For this purpose, Epo-TAgh and wild-type (WT) mice
were exposed to acute and chronic hypobaric hypoxia
(equivalent to 4500m). Results were compared to those
obtained in age-matched WT normoxic mice. We measured
plasma and muscle Epo concentrations, active HIF-1α and
VEGF protein by Enzyme-linked immunosorbent assay
(ELISA). To analyse the expression proﬁle of each VEGF
isoform, VEGFR1, VEGFR2 and EpoR mRNA, we used the
real-time reverse transcriptase-polymerase chain reaction
(RT-PCR). The expression of Epo mRNA was evaluated
ﬁrst by classical RT-PCR and second by real-time RT-
PCR. Moreover, the microvessel network was analysed in
gastrocnemiusmusclesasdescribedbyChariﬁetal.usingthe
speciﬁcplateletendothelialcelladhesionmolecule(PECAM)
antibody directed against CD31. The capillary-to-ﬁber ratio
(C/F), the number of capillaries around a single ﬁber and
the index of capillary tortuosity (LC/PF) were measured
to evaluate the development of elongated vessels running
parallel to the muscle ﬁbers and the new sprouts from loops
and cross connections [24].
2.MaterialsandMethods
2.1. Animal Model and Experimental Groups. For this study,
male Wild-Type F1 BL6/CBA (Charles River, L’Arbresle,
France) and male Epo deﬁcient SV-40T antigen (Epo-TAgh)
mice were divided randomly into six groups: (a) normoxic
wild-type (Nx WT); (b) normoxic Epo-Tagh (Nx Epo-
TAgh); (c) acute hypoxic wild-type (AHx WT); (d) acute
hypoxic Epo-TAgh (AHx Epo-TAgh); (e) chronic hypoxic
wild-type (CHx WT); and (f) chronic hypoxic Epo-TAgh
(CHx Epo-TAgh). At the moment of dissection all mice were
8 weeks old. The experimental procedures were performed
in agreement with the Guide for the Care and Use of
Laboratory Animals published by the National Institutes of
Health (NIH Publication No. 85–23, Revised 1996) and
were approved by the French “Minist` ere de l’Agriculture”
Guidelines (authorisation number A-93-008-01).
Mice undergoing AHx and CHx were housed for 24
hours and 14 days, respectively, in a hypoxic chamber
connected to a gas pump where air circulated at a pressure of
420mm Hg (∼4500m). Hypobaric hypoxia was maintained
by a vacuum source at ﬂow rates suﬃcient to prevent
CO2 build-up. Chamber pressure was interrupted 20–30
minutes three times a week for cleaning, and food and
water replacement. Pressure changes were achieved slowly
andtherenewalofairinthechamberwassuﬃcient toensure
the composition of atmospheric air. Normoxic groups were
kept in a normobaric normoxic environment (760mm Hg)
outside the hypobaric chamber. All animals were housed in
standard conditions (temperature 20–23◦C with a 12 hours
light: 12 hours dark cycle) and had free access to tap water
and food.
At the end of time of each experiment, the mice
were anaesthetized with pentobarbital, 60mg/Kg intraperi-
toneally. Two intra cardiac blood samples were taken
for hematocrit determination with a microcentrifuge
(MicrospinAMES,Germany)andhemoglobinmeasurement
(OSM 3, Radiometer, Copenhagen, Denmark).
Under sterile conditions, gastrocnemius muscles were
removed, rinsed in sterile phosphate buﬀered saline solution
(PBS). The muscles were snap frozen in liquid nitrogen or
mounted in tissue freezing embedding medium (Cryoblock,
Labonord, France) for immunohistochemistry techniques
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isopentane. Samples were stored at –80◦C until time of
analysis. The mice were then killed with a lethal dose of
pentobarbital.
2.2. Plasma and Muscle Epo Immunoassay. The quantitative
determination of mouse Epo concentration in plasma and
muscle extracts was assayed by Enzyme-Linked Immunosor-
bent assay (ELISA) by using the Quantikine Mouse Epo
Immunoassay (R&D systems Europe, Abingdon, UK).
Plasma collection and assay procedure were carried out fol-
lowing the manufacturer’s instructions. For determination
of Epo plasma concentration, Nx WT, Nx Epo-TAgh, AHx
WT and AHx Epo-TAgh were used (n = 4i ne a c hg r o u p ) .
The plasma was collected using heparin as an anticoagulant,
centrifuged at 13,000×g, 15 minutes at 4◦C and stored at –
20◦C. Because nothing is known about Epo concentration
in skeletal muscle, the gastrocnemius, soleus, plantaris,
extensor digitorum longus and tibialis anterior muscles
(hindlimb muscles) were mixed to ensure an adequate
extraction volume and a suﬃcient protein quantity to ensure
the detection by the kit. For this experiment all conditions
were tested (n = 5 in each group). These ﬁve muscles were
homogenized together in a very small volume of PBS (1:4
weight/volume) to concentratetotal proteins, centrifugedfor
10 minutes, 5,000×ga t4 ◦C and directly stored at –20◦C.
After 2 freeze-thaw cycles to break-up the cell membranes,
muscle homogenates were assayed without prior dilution
whereas plasma samples required a 2-fold dilution in a
calibrator diluent provided in the kit. A standard curve was
done in duplicate using a stock solution of Epo standard
to produce a 2-fold dilution series ranging from 3000 to
0pg/mL. In parallel, 50μLo fs a m p l ew e r ea d d e dt o5 0 μL
of assay diluent speciﬁc for mouse samples into each well
of a microplate coated with a monoclonal antibody against
mouse Epo and incubated for 2 hours on a microplate
shaker at room temperature. A positive control consisting
of a recombinant Epo solution, provided in the kit, was
also loaded. After washing, 100μL of a monoclonal antibody
against mouse Epo conjugated to horse radish peroxidase
(HRP) were added to each well and incubated for 2 hours on
a microplate shaker at room temperature. Finally, 100μLo f
substrate solution were added after 4 washes and incubated
for 30 minutes at room temperature on the benchtop in
the dark. After 30 minutes, the reaction was stopped using
100μL of a stop solution in each well. The optical density
was measured at 450 nm. The concentration of Epo (pg/mL)
detected in each sample was compared to the Epo standard
curve.Finally,datawereexpressedastheratioofthequantity
of Epo (in pg) to that of total protein (in mg) for muscles.
2.3. Determination of Active HIF-1α. Nuclear extracts of
gastrocnemius of Nx WT, Nx Epo-Tgh, AHx WT, AHx
Epo-TAgh, CHx WT and CHx Epo-TAgh mice (n = 5
per group) were obtained by using lysis buﬀer A: 10mM
HEPES (pH 7.9), 1.5mM MgCl2,10mM KCl, 0.5mM DTT,
0.1% NP-40, 2mM Na3VO4, 5mM NaF, an antiproteinase
coktail and lysis buﬀer B: 20mM HEPES (pH 7.9), 1.5mM
MgCl2,420mM NaCl, 0.5mM DTT, 25% glycerol, 2mM
Na3VO4, 5mM NaF and antiprotease coktail as described
in the protocol of DuoSet IC Mouse active HIF-1α (R&D
System, Europe, Abingdon, UK). The determination of
active HIF1-α has been carried out as described by the
manufacturer (R&D System, Europe, Abingdon, UK).
2.4. Total RNA Isolation and cDNA Synthesis. Total RNA
was extracted from the gastrocnemius muscle of mice from
diﬀerent groups (Nx, AHx and CHx from WT and Epo-
TAgh mice; n = 5 in each group) by using the RNeasy Mini
Kit and it was digested with RNase free DNase Set (Qiagen,
Courtaboeuf, France) following the method provided by the
manufacturer. RNA preparations were quantiﬁed by using
an ultraviolet visible recording spectrophotometer (LKB
PharmaciaUltrospec)usingabsorbenciesat260and280nm.
To evaluate the purity of the extracted RNA, absorbance
ratios at 260nm/280nm (RNA/protein) were determined.
We controlled the 260/280 ratio which was between 1.8 and
1.9, indicative of pure RNA. Reverse transcription (RT) was
carried out to synthesize the ﬁrst strand cDNA from 1.9 μg
of mRNA with the SuperScript III First-Strand Synthesys
System (Invitrogen, Carlsbad, CA, USA).
2.5. Semiquantitative RT-PCR. Polymerase chain reaction
(PCR)techniqueswereusedtoidentifytheexpressionofEpo
mRNA in the experimental samples. The cDNA sequences
forthegenesofinterestwereobtainedfromGenBank.Allthe
primerssequencesandRT-PCRparametersusedinthisstudy
are described in Table 1. The PCR reaction mix contained
10X reaction buﬀer, 50mM MgCl2,d N T Pm i x( 1 0m Me a c h
dATP, dGTP, dCTP and dTTP at neutral pH), 1μMp r i m e r s
of Epo or β-actin, Taq polymerase (Invitrogen, France),
cDNA and sterile water. PCR was carried out by using a
DNA Thermal Cycler (R&D Sytem, England) as follows:
95◦Cf o r5m i n u t e s ;t h e n3 5c y c l e sf o rβ-actin and 38 for
Epo of denaturation at 95◦C for 1 minute, annealing at 60◦C
for 1 minute and extension at 72◦C for 1 minute each. A
10 μL portion of the ampliﬁed PCR product was analysed
by electrophoresis on a 2% agarose gel that was stained
with ethidium bromide for visualization of DNA bands by
ultraviolet illumination. A 50–base pair (bp) ladder DNA
molecular weight marker was used (Fermentas, France) to
provide a size reference for the test reactions.
2.6. Real-Time RT-PCR. Real-time RT-PCR technique was
used to identify the distribution of VEGF isoforms, VEGFR1
VEGFR2 and EpoR in the RNA samples. The cDNA
sequences were obtained as described above and presented
in Table 1. The VEGF common forward primer is located
on exon 4, the VEGF120 reverse primer is located on the
boundary of exon 5 and exon 7, VEGF164 reverse primer is
located on the boundary of exon 5 and exon 8, and VEGF188
reverse primer is located on the boundary of exon 5 and
exon 6.
The Light Cycler FastStart DNA Master SYBR Green
I (Roche Biochemicals, Stockholm, Sweden) was used for
quantitative analyses of the generated cDNA. The RT-PCR
ampliﬁcations were performed in a total volume of 20μL,4 Journal of Biomedicine and Biotechnology
Table 1: Sequence and hybridization temperature (Tm) of speciﬁc primers.




VEGF120 GCCAGCACATAGAGAGAATGAGC GGCTTGTCACATTTTTCTGG 63◦C 94 NM 001025257
VEGF164 GCCAGCACATAGAGAGAATGAGC CAAGGCTCACAGTGATTTTCTGG 63◦C 97 M95200
VEGF188 GCCAGCACATAGAGAGAATGAGC AACAAGGCTCACAGTGAACGCT 63◦C 171 NM 001025250
VEGFR1 CGAACTCCACCTCCATGTTT TATCTTCATGGAGGCCTTGG 60◦C 116 NM 010228.3
VEGFR2 AGAGTTGGTGGAGCATTTGG TAGGCAGGGAGAGTCCAGAA 60◦C 125 NM 010612.2
Epo AATGGAGGTGGAAGAACAGG ACCCGAAGCAGTGAAGTGA 60◦C 155 NM 007942
EpoR GCTCCGGGATGGACTTCA GAGCCTGGTGCAGGCTACAT 60◦C 86 NM 010149
β-actin AGAGGGAAATCGTGCGTGAC CAATAGTGATGACCTGGCCGT 62◦C 138 NM 007393
containing 5μL cDNA sample, 4μL LightCycler-FastStart
DNA Master SYBR Green I, 0.5μLo fe a c hp r i m e r ,a n d
2.5mM MgCl2. For each reaction, the polymerase was
activated by a preincubation at 95◦Cf o r1 0m i n u t e s .
Ampliﬁcation was then performed for 45 cycles of switching
between 95◦C for 10s, gene dependant Tm for 5 to 8s,
and 72◦C for 8 to 15s depending on the length of the
amplicon and followed by a melting point analysis from
65 to 95◦C. The results were represented as threshold cycle
numbers (Ct values). Control cDNA of normoxic mouse
lung was diluted and ampliﬁed to create standard curves by
plotting Ct values versus cDNA templates. Relative amounts
of mRNA, normalised by β-actin were calculated from Ct
values according to the manufacturer’s description.
2.6.1. Calculation of Relative Quantiﬁcation Values. The
relativequantiﬁcationvalueswerecalculatedaccordingtothe
manufacturer’s protocol (Roche Biochemicals, Stockholm,
Sweden). The Cp represents the PCR cycle at which an
increase in ﬂuorescence above a baseline signal can be
detected. Cp value was used to calculate the amount of RT-
PCR product compared with the internal control, β-actin.
The Cp value of β-actin was subtracted from the gene Cp
valuetoevaluatethemeanchangeinCp ineachexperimental
group.
2.7. Analysis of VEGFA Protein Concentration by ELISA.
Gastrocnemius muscles from diﬀerent groups (Nx, AHx and
CHx from WT and Epo-TAgh mice; n = 4i ne a c hg r o u p )
were weighted and homogenized in 5-fold volume in ice cold
buﬀer (10mM tris, pH 8). The suspension was centrifuged
at 13,000g at 4◦C for 15 minutes. The protein content of
the supernatant was determined by the Bradford assay using
bovine serum albumin (BSA) as standard. The quantity of
total VEGFA in the gastrocnemius muscles from WT and
Epo-TAgh miceinnormoxiaandfollowingacuteandchronic
hypoxic exposure was determined by a commercial high-
sensitivity ELISA kit (DuoSet Kit) according to the manufac-
turer’s instructions (R&D Systems Europe, Abingdon, UK).
Measurements were done in duplicate.
2.8. Immunohistochemistry
2.8.1. Section Preparation. For visualization of vascular
endothelial cells we used the monoclonal antibody CD31
which recognizes platelet endothelial cell adhesion molecule
(PECAM-1), a glycoprotein strongly expressed in all
endothelial cells.Tothatend, serial10μmtran sv e r sesecti o n s
from the midbelly region of frozen gastrocnemius muscles
samples from Nx WT, Nx Epo-TAgh, CHx WT and CHx
Epo-TAgh (n = 5 in each group) were cut in a cryostat
(Leica, France) at −20◦Ca n dm o u n t e di nm i c r o s c o p e
slides (Superfrost Plus, Fisher Scientiﬁc, France). The slides
were ﬁxed in cold acetone and incubated in 3% hydrogen
peroxidase (H2O2) to inhibit any endogenous peroxidase.
Then, they were blocked with 3% BSA before incubating
with rat antimouse CD31/PECAM-1 monoclonal antibody
(BD Biosciences Pharmingen, France) diluted 1:100 in the
protein blocking solution. Tissue sections were incubated
with a biotynilated antirat secondary antibody (Dako,
France) diluted 1:200 in blocking solution. Staining was
carried out using streptavidin-HRP (Dako, France) and
revelation was done by incubating slides in the dark in
a3 ,3  -diaminobenzidine (DAB) solution (Sigma, France).
Negative controls were obtained by omitting the primary
or secondary antibody. The sections were counterstained
with haematoxylin (Sigma, France) and mounted in aqueous
mounting agent (Aquatex, Darmstadt, Germany).
Because the capillary tortuosity in muscles is a function
of sarcomere length, the longitudinal 10μm cryo-sections
were stained by using haematoxylin (Sigma, France) and
eosin (Sigma, France) to make sure it was constant between
the diﬀerent conditions. The length occupied by 10 consec-
utive sarcomeres was measured per longitudinal section in 2
samples of Nx and CHx with the software described below.
This technique of immunostaining does not allow to
identify the various types of blood vessels (arterioles, cap-
illaries or venules) nor the diameter of them. Consequently
we used “microvessel network” as a generic term.
2.8.2. Morphometry and Assessment of Microvessel Network.
Stained sections were studied under a light microscopeJournal of Biomedicine and Biotechnology 5
Table 2: Body weight, hematocrit and haemoglobin concentration in wild-type (WT) and Epo-Tagh mice in normoxia (Nx), acute hypoxia
for 24 hours (AHx) and chronic hypoxia for 14 days (CHx) (n = 14 in each group).
WT Epo-TAgh
Nx AHx CHx Nx AHx CHx
Body weight (g) 24.2 ± 1.3 23.1 ± 1.1 23.5 ± 0.9 23.0 ± 1.1 23.6 ± 1.3 23.1 ± 1.9
Muscle weight (g) 0.15 ± 0.03 0.12 ± 0.01 0.15 ± 0.03 0.15 ± 0.02 0.12 ± 0.02 0.13 ± 0.01
Hematocrit (%) 45.3 ± 1.6 51.7 ± 1.3∗ 60.3 ±1.6
∗# 19.3 ± 1.1$ 21.6 ± 1.5∗$2 7 ±1.9
∗$
[Haemoglobin] g/dL 17.3 ± 0.3 16.9 ± 0.4 19.2 ± 0.5∗ 6.7 ± 0.5$ 6.1 ± 0.2$ 7.1 ± 0.5$
Values are means ± SD.
∗Signiﬁcantly diﬀerent from corresponding Nx group, P<. 05; #, signiﬁcantly diﬀerent from corresponding AHx group, P<. 01; $, signiﬁcantly diﬀerent
from corresponding WT group, P<. 05.
connected to a digital camera (Coolpix 990, Nikon). Pho-
tographs were taken at x40 magniﬁcation. Image calibration
wasdonebytakingaphotoofamicrometricglasscoverslipat
X40 magniﬁcation. Explora Nova image analysing software
(Explora Nova Morpho, La Rochelle, France) was used to
analyse the images. To determine the microvessel network
we analysed two diﬀerent sections. On each section, we have
chosen two diﬀerent areas for the deep region and for the
superﬁcial region. Capillary density (CD) and capillary-to-
ﬁber ratio (C/F) were quantiﬁed for each entire area. All
transversely cut capillaries were counted and if a capillary
was sectioned longitudinally, it was counted as one each time
it crossed a junction between three or more muscle ﬁbers.
The individual ﬁber parameters were evaluated by counting
an average of 70 ﬁbers by area. For each individual ﬁber
the following parameters were evaluated: (a) the number
of capillaries around a single ﬁber (capillary contacts, CC);
(b) the CC relative to the area of the ﬁber (CCFA); (c) the
length of the contact between the microvessels and the ﬁbers
(LC); (d) the capillary-to-ﬁber ratio on an individual-ﬁber
basis (C/Fi); (e) ﬁber cross-sectional area (FA); and (f) ﬁber
perimeter (PF). Obliquity in ﬁber sectioning was assessed
by using the form factor (FF) that represents: (4π xﬁ b e r
area)/(ﬁber perimeter)2 (a perfect circle will have a FF of 1,
whereasaline’sFFwillapproachzero).Thecapillary-to-ﬁber
perimeter exchange (CFPE) index was calculated to obtain
an index of the size of the capillary-to-ﬁber interface and was
determined from the equation: CFPE index = (C/Fi)/P [25].
The index of capillary tortuosity can be indirectly
determined by LC/PF. This index is expressed as a percentage
of muscle ﬁber perimeters in contact with the capillary wall.
All quantitative analyses were blinded by the same
observer.
2.9. Statistical Analysis. Two-way analysis of variance
(ANOVA; hypoxia versus Epo deﬁciency) was carried out
and Newman-Keuls test was used for post hoc test. A
nonparametric Mann-Whitney test was exceptionally used
for plasma Epo measurements since the Nx WT group
was only three mice making impossible to perform a two-
way ANOVA. The statistical analyses were performed using
Stastitica software (StartSoft, Tulsa, OK). All values are
expressed as mean ± SD. Diﬀerences were considered to be
signiﬁcant at P ≤ .05.
3. Results
3.1.AnimalCharacteristics. Bodyandmuscleweights,hema-
tocrits and haemoglobin concentrations of Nx, AHx and
CHx of WT and Epo-TAgh mice are presented in Table 2.
Body and muscle weights were similar in all groups whether
submitted or not to hypoxia. Hematocrit and haemoglobin
concentrations were signiﬁcantly 57% and 61% lower in Nx
Epo-TAgh mice than in Nx WT group demonstrating severe
anaemia (global eﬀect, P<. 001). Exposure to hypoxia for 14
days induced a polycythemia in WT (P<. 05). Epo-TAgh
mice also responded to hypoxia exposure, and hematocrit
values were 40% higher in CHx than in Nx mice (P<. 05).
However, haemoglobin concentration in Epo-TAgh mice did
not change when compared to normoxic values.
3.2. Epo Is Not Expressed in Skeletal Muscle in both Normoxia
and Acute Hypoxia. I no r d e rt ov a l i d a t eo u rm o d e lw eﬁ r s t
determined the amount of Epo. We chose to measure the
plasma concentration in Nx and AHx conditions for 24
hours because the hypoxia-induced erythropoiesis activation
occurred during the early phase of exposure (5–9 days) [2]
with a peak of expression of Epo at 24 hours. The plasma
and muscle Epo measurements showed a strong reduction in
Epo-deﬁcient mice (Epo-TAgh mice) (Table 3). In Nx Epo-
TAgh mice,Epoplasmaconcentrationwas56%lowerthanin
Nx WT group (P<. 05). Acute hypoxia exposure increased
Epo plasma concentration in both groups, but remained 3-
fold lower than in AHx WT animals (P<. 05). Similar
results were reported for Epo muscle concentration which
was 2-fold lower in Nx Epo-TAgh mice than in Nx WT group
(P<. 05). Acute and chronic hypoxia exposure did not
change Epo concentration in the skeletal muscle in neither
WT nor Epo-TAgh mice. Those results raise the question of
the secretion of Epo within the skeletal muscle. Our results
of classical RT-PCR did not demonstrate any expression of
mRNA encoding Epo whatever the experimental condition
(Figure 1(a)). Those results were conﬁrmed by real-time RT-
PCR (data not shown).
3.3.mRNAEncodingEpoRisNotUpregulatedinEpo-Deﬁcient
Skeletal Muscles. Using the same transgenic model [13]w e
demonstrated an upregulation of mRNA encoding the EpoR
in the brain which suggests an optimization of Epo signalling6 Journal of Biomedicine and Biotechnology
Table 3: Plasma and muscle Epo concentration in wild-type (WT) and Epo-TAgh mice in normoxia (Nx), after acute hypoxia for 24 hours
(AHx) and chronic hypoxia for 14 days (CHx) (n = 4 or 5 in each group).
Plasma [Epo] pg/mL Muscle [Epo] pg/mg of total protein
Nx AHx Nx AHx CHx
WT 122 ± 16 460 ± 39∗ 0.121 ± 0.03 0.097 ± 0.02 0.128 ± 0.06
Epo-TAgh 53 ± 18$ 162 ± 25∗$ 0.060 ± 0.04$ 0.082 ± 0.02 0.101 ± 0.07
Values are means ± SD.
∗signiﬁcantly diﬀerent from corresponding Nx group, P<. 05; $, signiﬁcantly diﬀerent from corresponding WT group, P<. 05.
Table 4: Indices of the microvascular supply and morphological data of gastrocnemius muscle ﬁbers in normoxia (Nx), and after exposure
to chronic hypoxia for 14 days (CHx) (n = 5 in each group).
Nx CHx
Superﬁcial region Deep region Superﬁcial region Deep region
WT Epo-TAgh WT Epo-TAgh WT Epo-TAgh WT Epo-TAgh
Global microvessel indices
CD (cap/mm2) 546 ± 174 611 ± 95 1699 ± 350 1587 ± 180 601 ± 105 624 ± 81 1845 ± 393 1701 ± 211
C/F 1.33 ± 0.16 1.70± 0.17∗ 2.23 ± 0.29 2.69 ± 0.29∗ 1.27 ± 0.15 1.65 ± 0.26∗ 2.28 ± 0.20 2.62 ± 0.29∗
Individual ﬁber microvessels indices
CC 2.89 ± 0.63 3.57 ± 0.56∗ 5.20 ± 0.78 6.27 ± 0.54∗ 2.95 ± 0.16 3.54 ± 0.46∗ 5.22 ± 0.82 6.19 ± 0.41∗
C/Fi 1.05 ± 0.11 1.37 ± 0.21∗ 2.16 ± 0.26 2.46 ± 0.35∗ 1.09 ± 0.13 1.34 ± 0.20∗ 2.15 ± 0.19 2.58 ± 0.21∗
LC/PF (%) 8.96 ± 1.26 11.9 ± 0.93∗ 30.2 ± 7.3 35.4 ± 8.7 10.2 ± 1.84 12.56 ± 0.82∗ 32.5 ± 8.0 37.0 ± 3.90
Morphological data of muscle ﬁbers
FA (μm2) 2521 ± 286 2411 ± 188 1259 ± 158 1494 ± 165 2189 ± 314 2499 ± 204 1232 ± 246 1361 ± 133
PF (μm) 215 ± 17 222 ± 21 160 ± 16 173 ± 14 198 ± 13 220 ± 7 153 ± 18 165 ± 11
Form factor 0.63 ± 0.02 0.63 ± 0.03 0.64 ± 0.06 0.64 ± 0.03 0.62 ± 0.02 0.63 ± 0.02 0.65 ± 0.04 0.65 ± 0.04
Values are means ± SD;
Main eﬀect of Epo deﬁciency: signiﬁcantly diﬀerent from WT group: ∗P <. 05.
CD: capillary density; C/F: capillary-to-ﬁber ratio; CC: number of capillaries around single ﬁbers; C/Fi: individual capillary-to-ﬁber ratio; LC/PF: length of
the contact between microvessels and the ﬁber/perimeter of the ﬁbers; FA: ﬁber area; PF: perimeter.
to Epo deﬁciency. In the skeletal muscle we did not ﬁnd any
upregulation of EpoR mRNA (Figure 1(b)). Moreover, it can
be noticed that the amount of EpoR is extremely weak when
compared to β-actin (Figure 1(b)).
3.4. Epo Deﬁcient Gastrocnemius Does Not Exhibit Fiber
Atrophy and it Presents Developed Microvessel Network. We
hypothesisedthatEpodeﬁciencycouldinducechangesinthe
microvessel network of the skeletal muscle as well as muscle
ﬁber atrophy. Immunostaining analysis of CD 31/PECAM-
1 was designed to visualise the distribution of vessels in
gastrocnemius muscles (superﬁcial and deep region) of
WT and Epo-TAgh mice after exposure to chronic hypoxia
(Figure 2). The morphometric parameters measured are
reported in Table 4. The two-way ANOVA showed a main
global eﬀect of Epo deﬁciency in the microvessel network
whenexpressedin C/F,C/Fi andCC.Thesethreeparameters
were higher in Epo-TAgh mice when compared to WT (P<
.05; Table 4) in both superﬁcial and deep regions of the
gastrocnemius muscle (Figure 2).
The LC/PF ratio was higher in Epo-deﬁcient mice
comparedwithWTmice,butonlyinthesuperﬁcialregionof
gastrocnemius (+34% and +23% in Nx Epo-TAgh and CHx
Epo-TAgh groups, resp.; main global eﬀect of Epo deﬁciency,
P<. 05). No statistical diﬀerence was shown in the deep
regions, but the values of Epo-TAgh mice tended to be
higher than WT mice in normoxia and after chronic hypoxia
(Table 4). The absence of any change in FF showed that
the cross-sectional morphology of muscle ﬁbers remained
unchanged (Table 4). Taken together, the results of FF and
LC/PF suggest a change in microvessel tortuosity in the
superﬁcial region of the gastrocnemius muscle in Epo-TAgh
mice.
The CD, FA and PF were not signiﬁcantly altered in
any examined groups and experimental conditions (Table 4).
Equality, the CC expressed in relation to ﬁber area (CCFA)
and the C/Fi r a t i oe x p r e s s e di nr e l a t i o nt oﬁ b e rp e r i m e t e r
(CFPE) were similar in all groups, whether submitted to
hypoxia or not (data not shown).
3.4.1. Sarcomere Length. The sarcomere length of the gas-
trocnemius was homogeneous among myoﬁbrils of each
group (data not shown).Journal of Biomedicine and Biotechnology 7
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Figure 1: Expression of Epo and EpoR mRNA in gastrocnemius muscle of wild-type (WT) and Epo-TAgh mice in normoxia (Nx) and
following acute hypoxia for 24 hours (AHx) and chronic hypoxia for 14 days (CHx). (a) Semi-quantitative RT-PCR of Epo mRNA compare
to β-actin. (b) Quantitative determination of EpoR mRNA in all experimental conditions. Values are means ± SD.
3.5. Local Hypoxia Is Not Observed in Adult Epo-Deﬁcient
Gastrocnemius. Because Epo is required for oxygen delivery
we suggested that Epo deﬁciency could induce local hypoxia.
Then the amount of HIF-1α was evaluated in normoxia
as well as in hypoxia. The amount of active HIF-1α was
not changed between WT and Epo-TAgh mice in both
normoxia and hypoxia (Figure 3(a)). mRNA encoding HIF-
1α is unchanged in Nx Epo-TAgh mice compared to Nx
WT one (Figure 3(b)). When exposed to acute hypoxia both
groups exhibit an upregulation of HIF-1α mRNA (P<. 001;
Figure 3(b)) while no diﬀerence was observed in the CHx
groups.
3.6. VEGF Protein Is Not Over-Expressed in Epo-Deﬁcient
Gastrocnemius Muscle. We analysed the amount of VEGF
protein in gastrocnemius muscle of WT and Epo-TAgh
mice both in normoxia and submitted to acute and chronic
hypoxia by ELISA. The VEGF protein concentrations are
presented in Figure 3(c).
No signiﬁcant diﬀerence was observed in VEGF protein
level between WT and Epo-TAgh normoxic groups. In WT
mice, the level of VEGF protein increased by 29% (P<. 01)
after acute exposure to hypoxia. In contrast, VEGF protein
content was reduced by 21% after CHx, in comparison with
normoxic values (P<. 05). The VEGF protein content in
Epo-TAgh mice failed to change with hypoxia exposure.
In comparison with AHx WT, the amount of VEGF
protein was 30% lower in AHx Epo-TAgh (P<. 01) whereas
it was 28% higher in CHx Epo-TAgh than in CHx WT
(P<. 01).
3.7. Diﬀerential Regulation of mRNA VEGF120, 164 and
188 Isoforms and VEGFR1 and 2 mRNA. Using real-time
RT-PCR, we quantiﬁed the expression of mRNA spliced
variant isoforms VEGF120, VEGF164 and VEGF188 as well
as VEGFR1 and VEGFR2 of WT and Epo-Tagh in the
gastrocnemius muscle of Nx, AHx and CHx mice groups
in order to examine the responses of VEGF isoforms to
Epo deﬁciency and decreased oxygen transfer. Our results
showed that the expression of VEGF120 and VEGFR2 were
modulated in hypoxia and/or Epo deﬁciency only (Figures
4(a) and 4(e)). VEGF 120 mRNA was up regulated (P<
.001) in acute hypoxia in WT mice compared to Nx groups.













Superﬁcial region Deep region
Figure 2: Muscle cross-section of the superﬁcial ((a) to (d)) and deep region ((e) to (h)) of the gastrocnemius muscle of wild-type (WT)
and Epo-TAgh mice stained by using the monoclonal antibody antiCD31 for the detection of the microvesssel network in normoxia (Nx)
and following chronic hypoxia for 14 days (CHx). Epo deﬁciency develops the microvessel network in mice. Bars = 50μm.
mRNA was observed in CHx only (P<. 001). VEGFR2
mRNA was upregulated in Nx Epo-TAgh group compared
to Nx WT (P<. 001). In chronic hypoxia, VEGFR2 mRNA
were upregulated in both Epo and WT groups compared to
corresponding normoxic ones (Figure 4(e)).
The rate of expression of VEGF164 and VEGF188 mRNA
remained unaﬀected by either hypoxia exposure or Epo
deﬁciency (Figures 4(b) and 4(c)). VEGFR1 mRNA was
upregulated by acute hypoxia in Epo-Tagh mice compared
to Nx Epo-TAgh and AHx WT (P<. 01; Figure 4(d)).
No diﬀerence was observed in chronic hypoxia and/or in
normoxic Epo-deﬁcient mice compared to WT ones.
4. Discussion
In this work, we aimed to determine whether Epo deﬁciency
could be involved in the skeletal muscle ﬁbers atrophy and
the alteration of microvessel network. In fact, it has been
suggested that Epo could be an important growth factor
for skeletal muscle development and repair. Our principal
ﬁndingsare:(1)Epo-deﬁcientanemicmusclesdonotexhibit
atrophy in both normoxia and hypoxia; (2) microvessel
network of Epo-deﬁcient mice is improved compared to WT
mice; (3) when exposed to hypoxia Epo is not accumulated












































































































Figure 3: Quantitative determination of (a) activated HIF-α protein and (b) HIF-α m R N Aa n d( c )V E G Fp r o t e i ni nt h eg a s t r o c n e m i u s
muscle of wild-type (WT) and Epo-TAgh mice in normoxia (Nx) and following acute hypoxia for 24 hours (AHx) and chronic hypoxia
for 14 days (CHx). Values are means ± SD. ∗, signiﬁcantly diﬀerent from corresponding Nx group, P<. 01. #, signiﬁcantly diﬀerent from
corresponding WT group, P<. 05. &, signiﬁcantly diﬀerent from corresponding AHx group. #, P<. 05.
upregulation of VEGF120 and VEGFR2 in gastrocnemius
muscle; (4) EpoR expression is not upregulated by either
hypoxia or Epo deﬁciency.
Our transgenic model (Epo-TAgh)i sa b l et os u rvi v et o1 4
days in severe hypoxia (4500m) despite the weak expression
of Epo. In fact, in these mice, the expression of Epo gene
is reduced, but the production of Epo still exists [23]. The
amount of Epo is dramatically reduced in plasma resulting
in a severe anaemia in these mice while a slight reduction
is observed in hindlimb muscles. However, although Epo
availability was lower in Epo-TAgh than in WT mice after
acute exposure to hypoxia (24 hours), the Epo protein
expression remained responsive to the hypoxic stimulus as
previously described [23]. Actually, in mice submitted to
acute hypoxia, plasma Epo is increased in both WT and
Epo-TAgh compared to normoxic mice even if the Epo level
is considerably lower in Epo-TAgh t h a ni nW Tm i c e .I n
hindlimb muscles, we did not ﬁnd any diﬀerence between
Epo levels in normoxic and acute hypoxic mice. In rodent, it
has been demonstrated an upregulation of mRNA encoding
Epoinkidneyasearlyastheﬁrsthourofexposuretohypoxia
leading to a peak of plasma Epo between the 12th and the
24th h of exposure [26]. Similar results were obtained in
the brain [13]. Since we did not detect the presence of RNA
encodingEpoatanyexperimentalpoint,theweakamountof
Epo protein we measured in muscle probably corresponded
to the Epo present in capillaries or in the interstitial
environment of myoﬁbers. Those results do not support
the idea that Epo is secreted by the skeletal muscle when
exposed to both normoxia or hypoxia at rest as it has been
shown in rats submitted to exercise [27]. Furthermore, the
low amount of EpoR encoding mRNA as well as the absence
of regulation of its expression in Epo-deﬁcient or hypoxic
gastrocnemius consolidates the hypothesis by which Epo is
not an important growth factor in the skeletal muscle in our
experimental conditions. In order to explain the presence
of mRNA encoding EpoR in the gastrocnemius muscle we
suggest that few nonmuscle cells could express EpoR. Lately,
LeBaron et al. [28] demonstrated that cells dispersed in
the fascia of rat quadriceps were able to respond to Epo
injections by STAT5 phosporylation. Taken together these














































































































































































Figure 4: Quantitative determination of VEGF and VEGFR isoforms mRNA in the gastrocnemius muscle of wild-type (WT) and Epo-TAgh
mice in normoxia (Nx) and following acute hypoxia for 24 hours (AHx) and chronic hypoxia for 14 days (CHx). (a) VEGF120 mRNA.
(b) VEGF164 mRNA. (c) VEGF188 mRNA. (d) VEGFR1 mRNA. (e) VEGFR2 mRNA. Values are means ± SD. ∗, signiﬁcantly diﬀerent
from corresponding Nx group, P<. 01. #, signiﬁcantly diﬀerent from corresponding WT group, P<. 01. &, signiﬁcantly diﬀerent from
corresponding CHx group, P<. 05.
from bone marrow could explain the expression of EpoR.
Moreover, the injection of rHuEpo in musculocutaneous
tissues induces the upregulation of endothelial nitric oxide
synthase (eNOS) and prevents musculocutaneous tissues
from ischemic damage [29]. These results suggest that Epo
could have some undirect eﬀects on the skeletal muscle such
as increasing the perfusion of arteriolar or the mobilisation
of nonresident stem cells in traumatizing conditions. In our
work, we did not test these hypotheses.
In the present study, Epo deﬁciency does not induce
skeletal muscle atrophy even when mice are exposed to
hypoxia, but we observe the improvement of microvessel
network when determined through parameters evaluating
angiogenesis such as C/F, C/Fi, CC and LC/PF. The capillary
number per area of muscle (CD) is an unreliable index of
angiogenesis if the muscle ﬁbers enlarge or atrophy [30,
31]. Indeed, some studies showed that body and muscle
mass is reduced after exposure to hypoxia. These changesJournal of Biomedicine and Biotechnology 11
induce a decrease in muscle ﬁber size and an increase in
CD not necessarily by the formation of new capillaries
[32]. In our work, we did not ﬁnd a loss of body mass
or muscle and the FA was not decreased in Epo-deﬁcient
mice. The great variations of surface area measures can
explain the nonsigniﬁcant change in CD despite the increase
of C/F. Therefore, we may conclude that the improvement
of microvessel network can be attributed to angiogenesis
in both studied regions. The improvement of both C/F
and tortuosity (LC/PF) in the superﬁcial region is probably
due to the fact that glycolytic ﬁbers, which are predom-
inant in this region, are more sensitive to local hypoxia
[33].
Epo and VEGF are important growth factors involved
in angiogenesis [10]. Indeed, in vitro, these factors were
shown to stimulate endothelial cell migration and pro-
liferation, which are key steps in the formation of new
vessels [10, 34]. Our data are consistent with conclusions
of Suzuki et al. [12] suggesting that the lack of Epo
induces a default of oxygen supply to tissues which in turn
activates a locally HIF-VEGF dependent angiogenic pathway.
Although we did not demonstrate any accumulation of
either active HIF-1α or VEGF protein, we suggest that the
improvement of capillary network occurred during muscle
development. These results show that Epo is dispensable ﬁrst
for microvessel formation and maintenance in the skeletal
muscle.
In chronic altitude hypoxia, several biological responses
occur to compensate for the negative eﬀects of reduced
oxygen availability [35]. Nevertheless, there has been a
number of discrepancies in the literature about physiological
adaptations to altitude and angiogenesis in the skeletal
muscle (for review, see [36, 37]). Hansen-Smith et al. [38]
found an increased capillary density in the white part of
the gastrocnemius muscle but no change in the number of
capillaries around a single ﬁber in the red and white parts
of gastrocnemius of mice submitted to 7 and 21 days of
hypoxia (∼7200m). Smith and Marshall [39] showed that
an arteriolar remodelling within the skeletal muscle in rats
during acclimatisation to chronic hypoxia occurs between
the 7th and the 18th day of exposure to hypoxia (4500m).
Conversely, Snyder et al. [40]a n dO l f e r te ta l .[ 41] did not
ﬁnd any hypoxia-induced angiogenesis in murin models.
Deveci et al. [42] suggested that the angiogenic response
might be divergent between oxidative and glycolytic rat
muscles. For that reason we chose a regionalised muscle
for our experiments: the gastrocnemius. The deep region
of this muscle is characterized as predominantly fast-twitch
red ﬁbers and the superﬁcial region as predominantly fast-
twitch white ﬁbers [43]. Our results conﬁrm the idea that
chronic hypoxia does not provide a suﬃcient stimulus to
induce capillary growth in mice skeletal muscles at least
in the early phase of acclimatisation of hypoxia. Actually,
it has been described by some authors as a late accli-
matisation (up to 5 weeks) to hypoxia which consists in
skeletal muscle atrophy [44] inducing in some cases the
increase of capillary density (for review [32]). The real
cause of this atrophy is not yet well known and factors
such as intestinal malabsorption or inactivity have been
suggested to be involved in this late acclimatisation to
hypoxia. In this work we focused on the role of Epo on
the Epo-dependent early phase of acclimatisation, so we
may conclude that the lack of change in muscle capillary
bed and the absence of skeletal muscle ﬁber atrophy in
response to ambient hypoxia is not aﬀected by Epo deﬁ-
ciency.
All studies dealing with hypoxia, VEGF and skeletal
muscles have addressed the VEGF164, which is the major
isoform of VEGF in the skeletal muscle [41]. We did not
ﬁnd any changes in VEGF164 and VEGF188 expression
in both Epo-deﬁcient or hypoxic gastrocnemius muscles.
Interestingly, both Epo-deﬁcient and WT mice exhibit a
VEGF120 response to hypoxia. This response is combined
with the upregulation of VEGFR2 in WT mice. Among
all VEGF isoforms, VEGF120 has been shown to have the
weakest angiogenic eﬀect. VEGF120/120 mutants exhibit
severe defects in vessel network [16, 45]. Moreover, it has
been demonstrated that VEGF120 does not induce either
the activation or the accumulation of endothelial cells
in culture. Lately, it has been proposed that VEGF120,
when binding to VEGFR2 receptor, may be involved in
the control of dilatation and permeability of vessels [46]
especially on endothelial cells of the human umbilical cord.
Moreover, it has been demonstrated that VEGF120 in brain
melanoma was able to diﬀuse away from the tumour
in order to recruit vasculature from surrounding tissues
[47]. Taken together, these results may suggest that acute
hypoxia induces the upregulation of VEGF120 which acts
through VEGFR2 signalling and improves the recruitment
of existing capillaries in order to ameliorate oxygen supply
to the muscle. Surprisingly, the upregulation of VEGF120 in
Epo-deﬁcient gastrocnemius is delayed when compared to
WT. This phenomenon needs further investigation in order
to understand if this delay is due to (1) Epo deﬁciency;
(2) upregulation of VEGFR1, which is known to regulate
the action of VEGFR2, or (3) the fact that VEGFR2
is already over-expressed in Epo-deﬁcient mice. Further-
more, these results suggest a nonangiogenic adaptation of
microvessels when both groups of mice were exposed to
hypoxia but this hypothesis needs to be veriﬁed through
further investigation, using new imaging techniques, for
instance.
To conclude, this report showed that the gastrocnemius
muscle possesses the remarkable feat to compensate Epo
deﬁciency-induced anaemia by developing its microvessel
network. Therefore Epo deﬁciency alone is not a suﬃcient
factor to explain muscle deconditioning in patients suﬀering
from severe renal failure. Moreover, we showed that the
skeletal muscle exhibits an upregulation of VEGF120 and
VEGFR2 when submitted to hypoxia, which suggests an
improvement in the dilatation of pre-existing microvessel
n e t w o r ki no r d e rt oa m e l i o r a t eo x y g e ns u p p l y .
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